Literature DB >> 19895994

Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning.

Niraj C Patel1, Javier Chinen, Howard M Rosenblatt, I Celine Hanson, Robert A Krance, Mary E Paul, Stuart L Abramson, Lenora M Noroski, Carla M Davis, Filiz O Seeborg, Samuel B Foster, Kathryn S Leung, Betty S Brown, Jerome Ritz, William T Shearer.   

Abstract

BACKGROUND: The effect of pretransplantation conditioning on the long-term outcomes of patients receiving hematopoietic stem cell transplantation for severe combined immunodeficiency (SCID) has not been completely determined.
OBJECTIVE: We sought to assess the outcomes of 23 mostly conditioned patients with SCID and compare their outcomes with those of 25 previously reported nonconditioned patients with SCID who underwent transplantation.
METHODS: In the present study we reviewed the medical records of these 23 consecutive, mostly conditioned patients with SCID who underwent transplantation between 1998 and 2007.
RESULTS: Eighteen patients (median age at transplantation, 10 months; range, 0.8-108 months) received haploidentical mismatched related donor, matched unrelated donor, or mismatched unrelated donor transplants, 17 of whom received pretransplantation conditioning (with 1 not conditioned); 13 (72%) patients engrafted with donor cells and survive at a median of 3.8 years (range, 1.8-9.8 year); 5 (38%) of 13 patients require intravenous immunoglobulin; and 6 of 6 age-eligible children attend school. Of 5 recipients (median age at transplantation, 7 months; range, 2-23 months) of matched related donor transplants, all 5 engrafted and survive at a median of 7.5 years (range, 1.5-9.5 year), 1 recipient requires intravenous immunoglobulin, and 3 of 3 age-eligible children attend school. Gene mutations were known in 16 cases: mutation in the common gamma chain of the IL-2 receptor (IL2RG) in 7 patients, mutation in the alpha chain of the IL-7 receptor (IL7RA) in 4 patients, mutation in the recombinase-activating gene (RAG1) in 2 patients, adenosine deaminase deficiency (ADA) in 2 patients, and adenylate kinase 2 (AK2) in 1 patient. Early outcomes and quality of life of the previous nonconditioned versus the present conditioned cohorts were not statistically different, but longer-term follow-up is necessary for confirmation.
CONCLUSIONS: Hematopoietic stem cell transplantation in patients with SCID results in engraftment, long-term survival, and a good quality of life for the majority of patients with or without pretransplantation conditioning.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19895994      PMCID: PMC3271026          DOI: 10.1016/j.jaci.2009.08.041

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  17 in total

1.  Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European group for bone marrow transplantation and the european society for immunodeficiency.

Authors:  Y Bertrand; P Landais; W Friedrich; B Gerritsen; G Morgan; A Fasth; M Cavazzana-Calvo; F Porta; A Cant; T Espanol; S Müller; P Veys; J Vossen; E Haddad; A Fischer
Journal:  J Pediatr       Date:  1999-06       Impact factor: 4.406

2.  A monoclonal antibody reactive with human peripheral blood monocytes.

Authors:  J Breard; E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  J Immunol       Date:  1980-04       Impact factor: 5.422

3.  In vitro T cell depletion using Campath 1M for mismatched BMT for severe combined immunodeficiency (SCID).

Authors:  A M Dickinson; M M Reid; M Abinun; J Peak; K Brigham; J Dunn; A J Cant
Journal:  Bone Marrow Transplant       Date:  1997-02       Impact factor: 5.483

4.  Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.

Authors:  C A Keever-Taylor; C Bredeson; F R Loberiza; J T Casper; C Lawton; D Rizzo; W H Burns; D A Margolis; D H Vesole; M Horowitz; M J Zhang; M Juckett; W R Drobyski
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

5.  Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.

Authors:  R H Buckley; S E Schiff; R I Schiff; L Markert; L W Williams; J L Roberts; L A Myers; F E Ward
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

6.  Long-term chimerism and B-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B cells: A single-center study of 22 patients.

Authors:  E Haddad; F Le Deist; P Aucouturier; M Cavazzana-Calvo; S Blanche; G De Saint Basile; A Fischer
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

7.  Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation.

Authors:  R H Buckley; S E Schiff; H A Sampson; R I Schiff; M L Markert; A P Knutsen; M S Hershfield; A T Huang; G H Mickey; F E Ward
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

8.  Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis.

Authors:  Mary Dell Railey; Yuliya Lokhnygina; Rebecca H Buckley
Journal:  J Pediatr       Date:  2009-10-09       Impact factor: 4.406

9.  Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study.

Authors:  William T Shearer; Howard M Rosenblatt; Rebecca S Gelman; Rebecca Oyomopito; Susan Plaeger; E Richard Stiehm; Diane W Wara; Steven D Douglas; Katherine Luzuriaga; Elizabeth J McFarland; Ram Yogev; Mobeen H Rathore; Wende Levy; Bobbie L Graham; Stephen A Spector
Journal:  J Allergy Clin Immunol       Date:  2003-11       Impact factor: 10.793

Review 10.  Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution.

Authors:  Rebecca H Buckley
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

View more
  21 in total

1.  Early vs. delayed diagnosis of severe combined immunodeficiency: a family perspective survey.

Authors:  Alice Chan; Christopher Scalchunes; Marcia Boyle; Jennifer M Puck
Journal:  Clin Immunol       Date:  2010-10-28       Impact factor: 3.969

2.  Immune reconstitution after HSCT in SCID-a cohort of conditioned and unconditioned patients.

Authors:  Uri Manor; Atar Lev; Amos J Simon; Daphna Hutt; Amos Toren; Bella Bielorai; Lior Goldberg; Tali Stauber; Raz Somech
Journal:  Immunol Res       Date:  2019-06       Impact factor: 2.829

3.  Genotype, phenotype, and outcomes of nine patients with T-B+NK+ SCID.

Authors:  Grace P Yu; Kari C Nadeau; David R Berk; Geneviève de Saint Basile; Nathalie Lambert; Perrine Knapnougel; Joseph Roberts; Kristina Kavanau; Elizabeth Dunn; E Richard Stiehm; David B Lewis; Dale T Umetsu; Jennifer M Puck; Morton J Cowan
Journal:  Pediatr Transplant       Date:  2011-08-23

4.  An analysis and decision tool to measure cost benefit of newborn screening for severe combined immunodeficiency (SCID) and related T-cell lymphopenia.

Authors:  Vicki Modell; Megan Knaus; Fred Modell
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

5.  IL-21 is the primary common γ chain-binding cytokine required for human B-cell differentiation in vivo.

Authors:  Mike Recher; Lucinda J Berglund; Danielle T Avery; Morton J Cowan; Andrew R Gennery; Joanne Smart; Jane Peake; Melanie Wong; Sung-Yun Pai; Sachin Baxi; Jolan E Walter; Umaimainthan Palendira; Gillian A Tangye; Michael Rice; Shannon Brothers; Waleed Al-Herz; Hans Oettgen; Hermann Eibel; Jennifer M Puck; Federica Cattaneo; John B Ziegler; Silvia Giliani; Stuart G Tangye; Luigi D Notarangelo
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

6.  Rapid reconstitution of antibody responses following transplantation of purified allogeneic hematopoietic stem cells.

Authors:  Jessica A Linderman; Judith A Shizuru
Journal:  J Immunol       Date:  2011-02-28       Impact factor: 5.422

7.  Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management.

Authors:  Linda M Griffith; Morton J Cowan; Luigi D Notarangelo; Jennifer M Puck; Rebecca H Buckley; Fabio Candotti; Mary Ellen Conley; Thomas A Fleisher; H Bobby Gaspar; Donald B Kohn; Hans D Ochs; Richard J O'Reilly; J Douglas Rizzo; Chaim M Roifman; Trudy N Small; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

8.  Effects of conditioning regimens and T cell depletion in hematopoietic cell transplantation for primary immune deficiency.

Authors:  Brandon M Triplett; Chong Wang; Jie Yang; Mari Dallas; Christine Hartford; Vanessa Howard; Asha Pillai; David Shook; Ashok Srinivasan; Joseph Laver; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2012-07-27       Impact factor: 5.742

9.  Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience.

Authors:  William T Shearer; Elizabeth Dunn; Luigi D Notarangelo; Christopher C Dvorak; Jennifer M Puck; Brent R Logan; Linda M Griffith; Donald B Kohn; Richard J O'Reilly; Thomas A Fleisher; Sung-Yun Pai; Caridad A Martinez; Rebecca H Buckley; Morton J Cowan
Journal:  J Allergy Clin Immunol       Date:  2013-11-28       Impact factor: 10.793

10.  Post-transplantation B cell function in different molecular types of SCID.

Authors:  Rebecca H Buckley; Chan M Win; Barry K Moser; Roberta E Parrott; Elisa Sajaroff; Marcella Sarzotti-Kelsoe
Journal:  J Clin Immunol       Date:  2012-09-22       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.